6:07 PM
 | 
Sep 06, 2007
 |  BC Extra  |  Top Story

Alpharma gets U.S. rights to Diractin

Idea (Munich, Germany) granted ALO exclusive U.S. rights to commercialize Diractin (formerly IDEA-033) to treat pain associated with osteoarthritis (OA). Idea will fund and conduct two Phase III studies to support an NDA...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >